Is veno-occlusive disease a specific syndrome or the exacerbation of physiopathologic hemostatic changes in hematopoietic stem cell transplantation (HSCT)?

Thrombosis Research

Volumn 99, Issue 5, 2000, Pages 439-446

  Villalón, Lucía ^a   Avello, Angel García ^a   César, Jesús ^a   Odriozola, Jesús ^a   López, Javier ^a   Oteyza, Jaime Pérez ^a   Laraña, José García ^a   Cantalapiedra, Alberto ^a   Navarro, José Luis ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Endothelial damage; HSCT; Hypercoagulability; VOD

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; PROTEIN C; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; DISEASE EXACERBATION; ENDOTHELIUM LESION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; MALE; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; RISK FACTOR; SYNDROME; VEIN OCCLUSION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CHOLESTASIS; DIAGNOSIS, DIFFERENTIAL; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYSIS; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOSTASIS; HUMANS; INCIDENCE; KIDNEY FUNCTION TESTS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SYNDROME; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VASCULAR DISEASES; VASCULAR HEMOSTATIC DISORDERS;

EID: 0034283308     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00269-3     Document Type: Article

References (31)

1. Jones RJ, Lee KSK, Beschorner WE et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987;44(6):778-83.
2. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995;85(11):3005-20.
3. Richardson P, Elias A, Krishnan A et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high risk population. Blood 1998;92:737-44.
4. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort of 355 patients. Ann Intern Med 1993;118:255-67.
5. Shulman HM, Hinterberger W. Hepatic venoocclusive disease - liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992;10:197-214.
6. Carreras E, Bertz H, Arcese W et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European group for blood and marrow transplantation. Blood 1998;92:3599-3604.
7. McDonald GB, Sharma P, Matthews DE et al. Venoocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984;4 (1):116-22.
8. Bearman SI, Anderson GL, Mori M et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993;11:1729.
9. Thomas ED, Storb R, Clift RA. Bone Marrow Transplantation I and II. New England J Med 1975;292:832-902.
10. Hagglund H, Ringden O, Remberger S et al. Risk factors for hepatic veno-occlusive disease in 500 allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1997;19:s17.
11. Carreras E, Tomás JF, de la Rubia J et al. Incidencia y evolutión de la enfermedad veooclusiva hepática (EVOH) en el trasplante de progenitures hematopoyéticos (TPH) en Espana: resultados del estudio prospectivo del European group for blood and marrow transplantation (EBMT). Haematologica 1997;82:210a.
12. Rozman C, Carreras E, Qian C et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 1996;17:75-80.
13. Fisher DC, Vredenburgh JJ, Petros WP et al. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to marked reduction in veno-occlusive disease of the liver. Bone Marrow Transplant 1998;21;117-22.
14. Rabinowitz J, Petros WP, Stuart A et al. Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support. Blood 1993;81:2452-9.
15. Bazarbachi A, Scrobohaci ML, Gisselbrecht C et al. Changes in protein C, factor VII and endothelial markers after autologous bone marrow transplantation: possible implications in the pathogenesis of veno-occlusive disease. Nouv Rev Fr Hematol 1993;35:135-40.
16. Collins P, Jones L, Uthayakumar et al. Haemostatic changes in uncomplicated bone marrow transplants. Bone Marrow Transplant 1991; (Suppl 2)7:54.
17. Collins PW, Gutteridge CN, O'Driscoll A et al. von Willebrand factor as a marker of endothelial activation following BMT. Bone Marrow Transplant 1992;10:499-506.
18. Collins P, Roderick A, O'Brian D et al. Factor Vila and other haemostatic variables following bone marrow transplantation. Thromb Haemost 1994;72(1):28-32.
19. Scrobohaci ML, Drouet L, Monen-Mansi A et al. Liver veno-occlusive disease after bone marrow transplantation. Changes in coagulation parameters and endothelial markers. Thromb Res 1991;63(5):509-19.
20. Tsakiris DA, Marbet GA, Tichelli A et al. Aktivierung endothel-abhängiger hämostatischer faktoren nach knochenmarktransplantation. Schweiz Med Wochenschr 1995;125(9):416-9.
21. Park YD, Yasui M, Yoshimoto T et al. Changes in hemostatic parameters in hepatic venoocclusive disease following bone marrow transplantation. Bone Marrow Transplant 1997;19:915-20.
22. Catani L, Gugliotta L, Mattioli Belmonte M et al. Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies. Bone Marrow Transplant 1993;12:253-9.
23. Faioni EM, Krachmalnicoff A, Bearman SI et al. Naturally ocurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venoocclusive disease of the liver. Blood 1993;81(12):3458-62.
24. Gordon B, Haire W, Kessinger A et al. High frequency of antithrombin III and protein C deficiency following autologous bone marrow transplantation for lymphoma. Bone Marrow Transplant 1991;8:497-502.
25. Harper PL, Jarvis J, Jennings I et al. Changes in the natural anticoagulants following bone marrow transplantation. Bone Marrow Transplant 1990;5:39-42.
26. Tabbara IA, Ghazal CD, Ghazal HH. Early drop in protein C and antithrombin III is a predictor for the development of venoocclusive disease in patients undergoing hematopoietic stem cell transplantation. J Hematother 1996;5:79-84.
27. Vannucchi AM, Rafanelli D, Longo G et al. Early hemostatic alterations following bone marrow transplantation: a prospective study. Hematologica 1994;79:519-25.
28. Cerveró C, Garcia Avello A, Villalón L et al. Inhibition de la fibrinolisis y PAI-1 elevado en transplante de médula osea. Asociación de enfermedad veno oclusiva hepática con niveles elevados de TNF-alfa. Sangre 1994;39:103(abstr. 352).
29. Gómez-Roncero MI, Cabrera R, Díez JL et al. Elevatión de PAI-1 en la enfermedad venooclusiva hepática (EVO) en el post-TMO. Sangre 1995;40:108(abstr. 365).
30. Salat C, Holler E, Reinhardt B et al. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease. Bone Marrow Transplant 1994;14:747-50.
31. Salat C, Holler E, Kolb HJ et al. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marow transplantation. Blood 1997;89:2184-8.